• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Acusphere Schedules Conference Call and Webcast to Present RAMP-2 Clinical Trial Results for Imagify(TM) (Perflubutane Polymer Microspheres) Injectable Suspension

Posted on: Monday, 30 April 2007, 18:00 CDT

Acusphere, Inc. (NASDAQ: ACUS) today announced that it will host a conference call and webcast to discuss the top-level results from the second Imagify Phase 3 pivotal clinical trial, RAMP-2 on May 1, 2007, at 8:30 AM ET. The Company indicated that it intends on issuing, prior to the conference call, a press release summarizing the results of the trial. The conference call will include an opportunity for analyst and investor questions and answers.

RAMP-2 trial results are scheduled to be presented by Sherri C. Oberg, President and Chief Executive Officer of Acusphere, Dr. Richard Walovitch, Senior Vice President of Clinical Research and Dr. Michael Picard, Director of Clinical Echocardiography at Massachusetts General Hospital.

This conference call and related slides will be accessible to hear and review via the Company's website at www.acusphere.com.

Dial in details: Date: May 1, 2007 Time: 8:30 AM ET Dial in: Domestic - 866-713-8564 International - 617-597-5312 Passcode: 10025502

About Imagify™

Imagify™ is an investigational new drug developed to assess perfusion using ultrasound for the detection of coronary artery disease. Myocardial perfusion is blood flow in the heart muscle and is a sensitive marker of coronary artery disease. Currently, perfusion information is not available using cardiac ultrasound but must be obtained using a nuclear stress test, which is the most frequently used imaging procedure for detecting coronary artery disease. Imagify is designed to provide real-time perfusion information with quicker results, lower cost and no exposure to radiation compared with nuclear stress tests. Imagify was designed to be used with commercially available ultrasound equipment and established imaging techniques. More than 10 million stress imaging procedures are done each year in the U.S. to detect heart disease, the leading cause of death in the United States. The Company estimates that the potential annual U.S. market opportunity for Imagify exceeds $2 billion.

About Acusphere, Inc.

Acusphere (NASDAQ: ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's initial product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, Imagify, is a cardiovascular drug in Phase 3 clinical development. For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" and "Imagify" are trademarks of Acusphere, Inc.

Source: Business Wire

More News in this Category